GeneDx (WGS) 44th Annual J.P. Morgan Healthcare Conference summary

2025 performance and growth outlook

• Achieved over 30% growth in volume and revenue, reaching $427 million in 2025, with exome/genome revenue up 54% and volumes up 30.5% year-over-year.

• Adjusted gross margin for 2025 was 30.5%, with positive adjusted net income and $172 million cash on hand.

• Projecting $540–$555 million in revenue for 2026, with 33–35% growth and continued profitability and at least 70% adjusted gross margin.

• Added 30% more tests to the Infinity database in 2025, surpassing the prior 24 years combined.

• Increased sales force to 75 reps to drive earlier diagnoses and market penetration.

Industry leadership and technology

• Holds 80% market share in pediatric and rare disease genetic testing, with strong brand recognition among geneticists and pediatric specialists.

• Recognized as the top brand with FDA breakthrough device designation and trusted by leading health systems.

• Infinity database includes over 1 million exomes/genomes, >2.5 million genetic tests, 8 million health records, and 7 million phenotypic data points.

• AI and proprietary machine learning models accelerate diagnosis accuracy, variant interpretation, and product improvement.

• Delivers diagnoses twice as accurately as the next largest database, with rapid and ultrarapid genome tests providing answers in as soon as 48 hours.

Market expansion and new opportunities

• Entering general pediatrician, prenatal, NICU, and adult specialist markets in 2026, focusing on early intervention and improved outcomes.

• Developed a one-minute ordering workflow for pediatricians, launching mid-year, and pediatricians are now a key growth segment.

• Expanding adult testing for conditions like epilepsy and autism, and moving into prenatal diagnostics for late-term pregnancies.

• International expansion enabled by the acquisition of Fabric Genomics, supporting decentralized testing and centralized intelligence.

• Pursuing biopharma and data business opportunities, leveraging the Infinity dataset for drug discovery and innovation.